NCT01325090

Early Administration of Botox® in Neuropathic Pain Due to Thoracoscopy or Thoracotomy

Early Administration of Botulinum Toxin Type A (Botox®) in Neuropathic Pain Due to Thoracoscopy or Thoracotomy: a Randomized, Double Blind, Placebo Controlled Study

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University Hospital, Limoges · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Botulinum toxin type A has been reported to inhibit the release of various pain neurotransmitters (SP, CGRP, glutamate) responsible for neurogenic inflammation, a process that results from the sensitization of C-fiber nociceptors (peripheral sensitization). This action is probably responsible for the analgesic effect of botulinum toxin type A recently demonstrated in patients with neuropathic pain of peripheral origin.In those studies, patients had been suffering for years. The investigators can hypothesizes that earlier administration of Botox in the course of neuropathic pain might prevent central sensitization, that is secondary to peripheral sensitization. The investigators can hope to increase efficacy of Botulinum toxin type A injections and to prevent chronification of pain.

Conditions

• Pain Due to Certain Specified Procedures
• Neuropathic Pain

Interventions

Type	Name	Description
DRUG	BOTOX	A syringe of 1 ml contain 25 Allergan units.
OTHER	PLACEBO	The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.

Timeline

• Start date: 2011-05-01
• Primary completion: 2013-11-01
• Completion: 2014-11-01
• First posted: 2011-03-29
• Last updated: 2018-08-13